International Desk: The first drug to slow the destruction of the brain in Alzheimer’s has been heralded as momentous and historic.
The research breakthrough ends decades of failure and shows a new era of drugs to treat Alzheimer’s – the most common form of dementia – is possible, reports BBC.
Yet the medicine, lecanemab, has only a small effect and its impact on people’s daily lives is debated. And the drug works in the early stages of the disease, so most would miss out without a revolution in spotting it.
Lecanemab attacks the sticky gunge – called beta amyloid – that builds up in the brains of people with Alzheimer’s. For a medical field littered with duds, despair and disappointment, some see these trial results as a triumphant turning point.
Alzheimer’s Research UK said the findings were “momentous”.
